Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Comparative, Multicenter, Phase II Study of the Efficacy and Safety of REGorafenib Versus Tamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression

NCT02584465 is registered in ClinicalTrials.gov with ARCAGY/ GINECO GROUP as lead sponsor.

NCT NCT02584465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02584465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Comparative, Multicenter, Phase II Study of the Efficacy and Safety of REGorafenib Versus Tamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression
Lead sponsor
ARCAGY/ GINECO GROUP
Phase
Phase 2
Overall status
Completed
Start date
August 28, 2015
Completion date
September 19, 2021
Enrollment
68 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian carcinoma